Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(19 sites) United States
Retinal Consultants of Arizona LTD, Retinal Research Institute, Phoenix, Arizona Jules Stein Eye Institute, Los Angeles, California Stanford University Byers Eye Institute, Palo Alto, California Kaiser Permanente Riverside Medical Center, Riverside, California Retina Consultants of Southwest Florida & National Ophthalmic Research Institute, Fort Myers, Florida Retina Specialty Institute, Pensacola, Florida Emory University Eye Center, Atlanta, Georgia University Retina and Macula Associates, Oak Forest, Illinois Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office, Boston, Massachusetts Ophthalmic Consultants of Boston, Boston, Massachusetts University of Michigan Kellog Eye Center, Ann Arbor, Michigan Deep Blue Retina, Southaven, Mississippi NJ Retina, New Brunswick, New Jersey Mid-Atlantic Retina, Philadelphia, Pennsylvania Tennessee Retina, PC, Nashville, Tennessee Retina Foundation of the Southwest, Dallas, Texas Valley Retina Institute, McAllen, Texas University of Washington, Seattle, Washington Spokane Eye Clinical Research, Spokane, Washington